dm-4

DM4 (Ravtansine) can be used in the preparation of antibody drug conjugate and it is an antitubulin agent. It can inhibit cell division.

DM4-SMe is a cytotoxic part of antibody-drug conjugates (ADCs) and a metabolite of antibody-maytansin conjugates (AMCs) and tubulin inhibitors, which can also be stabilized by disulfide bonds or thioether The bond binds to the antibody. The IC50 of DM4-SM

Maytansinoid DM4, a thiol-containing maytansine derivative, is a highly potent cytotoxic moiety utilized in ADC applications.

DM4-SMCC, a non-cleavable drug-linker conjugate for antibody-drug conjugates (ADC), leverages the antitumor efficacy of DM4 (an antitubulin agent) through attachment with the SMCC linker, exhibiting antitumor activity[1].

DM4-SPDP, a drug-linker conjugate, integrates the antitubulin agent DM4 with the linker SMCC, facilitating the creation of antibody drug conjugates[1]. Additionally, SPDP serves as a short-chain crosslinker enabling amine-to-sulfhydryl conjugation, leveraging NHS-ester and pyridyldithiol groups to establish cleavable (reducible) disulfide bonds with cysteine sulfhydryls[2][3].

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

DBA-DM4 is a drug-linker conjugate used in antibody-drug conjugate (ADC) synthesis, combining the tubulin inhibitor DM1 with the SPDP linker [1].

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

Sulfo-PDBA-DM4 is a drug-linker conjugate for antibody-drug conjugate (ADC) applications, combining the potent tubulin inhibitor DM4 with the gluthatione-cleavable linker Sulfo-PDBA. This configuration harnesses DM4's cytotoxic potential through Sulfo-PDBA's targeted delivery mechanism.

Lys-Nε-SPDB-DM4 is a drug-linker conjugate that integrates the tubulin inhibitor DM4 with the linker Lys-Nε-SPDB, enabling the formation of an antibody-drug conjugate (ADC).

S-Me-DM4 is an intracellular enzyme S-methylated metabolite of DM4, a maytansinoid with microtubule-depolymerizing properties and potent cytotoxicity, employed as an Antibody-Drug Conjugate (ADC) cytotoxin [1].

Tusamitamab ravtansine (SAR-408701) is a DM4-linked anti-CEACAM5 antibody-drug conjugate (ADC) comprising a humanized monoclonal antibody targeting carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) conjugated to a cytotoxic maytansinoid, selectively engaging CEACAM5-positive tumor cells [1].

DM4-D6 is a deuterated form of DM4, an antimicrotubule agent that inhibits cell division. DM4 (T15141-GMP) is utilized in the preparation of antibody-drug conjugates (ADCs).

Anti-CCL2 (Carlumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the human-derived anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked to the microtubule inhibitor DM4 via the SPDB linker. The toxic component and linker of the ADC are sulfo-SPDB-DM4. This compound is utilized in cancer research.

Anti-SLC34A2 (Lifastuzumab)-SPDB-DM4 is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody, Lifastuzumab, linked via SPDB to the tubulin inhibitor DM4. The toxic component and linker of this ADC is sulfo-SPDB-DM4. This compound can be utilized for cancer research.

Indatuximab ravtansine (BT-062) is an antibody-drug conjugate (ADC) (Antibody-Drug Conjugates (ADCs)) that consists of a murine-human chimeric form based on B-B4, which specifically targets CD138, linked via a disulfide bond to the maytansinoid drug DM4. It exhibits antitumor activity.

Human IgG1-sulfo-SPDB-DM4, ADC Control is an ADC control reagent that can be used as an isotype or negative control for IgG1-sulfo-SPDB-DM4-based ADC studies.

ADC Control Human IgG1-DM4 serves as the isotype control for ADC Human IgG1-DM4. It comprises an antibody portion identified as HumanIgG1kappa, Isotype Control, whereas the toxic molecule and linker components are SPDB-DM4.

OMDM-4 is a selective and metabolically stable anandamide cellular uptake (ACU) inhibitor with a Ki of 17.7 μM.

DM-4111, one of the primary monohydroxy metabolites of Tolvaptan, is an effective vasopressin V2 receptor (vasopressin V2 receptor) inhibitor. By inhibiting water reabsorption in renal tubules, it facilitates the excretion of electrolyte-free water. DM-4111 holds potential for research in cardiovascular diseases.

DM-4107 is a primary metabolite of Tolvaptan, primarily metabolized by the CYP3A4 enzyme in the liver. In SCHH cells, DM-4107 inhibits the human liver transport proteins NTCP, BSEP, MRP3, and MRP4, with IC50 values of 95.6, 119, 61.2, and 37.9 μM respectively, affecting bile acid transport. It is applicable for research on autosomal dominant polycystic kidney disease (ADPKD).

DM-4103 is a primary metabolite of Tolvaptan, predominantly metabolized by the CYP3A4 enzyme in the liver. In SCHH cells, DM-4103 inhibits the human liver transport proteins NTCP, BSEP, MRP2, MRP3, and MRP4 with IC50 values of 16.3, 4.15, 51.0, 44.6, and 4.26 μM, respectively, and affects bile acid transport. DM-4103 is applicable for research in autosomal dominant polycystic kidney disease (ADPKD).

KDM4-IN-4 is a histone lysine demethylase 4 (KDM4) inhibitor that primarily targets the Tudor domain of KDM4A and exhibits anticancer activity. KDM4-IN-4 has an affinity for the KDM4A Tudor domain of approximately 80 μM. KDM4-IN-4 inhibits the binding of H3K4Me3 to the Tudor domain in cells, with an EC50 of 105 μM. KDM4-IN-4 can be used in cancer research.

Zavondemstat (QC8222) is an orally active, selective inhibitor of the histone lysine demethylase 4 (KDM4) family, with an IC₅₀ of ≤ 0.08 μM against human KDM4A–D and a K₊₀ of 0.52 μM against human KDM4C. Zavondemstat activates tumor suppressor genes, induces apoptosis, causes S-phase cell cycle arrest, and inhibits cancer cell proliferation. In in vivo studies, Zavondemstat inhibits tumor growth and induces tumor regression. Zavondemstat can be used in cancer research.